Wolfgang Oster, M.D., PhD.
Chief Executive Officer
Dr. Oster has had successful careers in academia, in the pharma/biotech corporate world and in the investment industry. He received board certifications for internal medicine, hematology, and oncology, and served as Adjunct Professor at the Brown Medical School and at the University of Freiburg, Germany. He is the author of more than 100 publications and a recipient of the Johann Georg Zimmermann Award for Cancer Research. As a C-level Executive he worked at Behringwerke/Hoechst, and later at US BioScience and NeoRx before joining PolyTechnos Venture Partners as Managing Partner. During his tenure as Executive, Board Member and Investor he oversaw multiple drug, diagnostic and medical device projects from earliest stages to market introduction in all relevant global markets. He was involved in the development and approval of widely recognized therapies in oncology and hematology indications, including hematopoietic growth factors, cytokines, monoclonal antibodies, cytotoxic and cytoprotective agents, methylation-based technologies for diagnostic purposes, as well as interventional technologies in neurology and cardiology. At US BioScience he was instrumental as Chief Medical Officer in the successful merger with Medimmune. At PolyTechnos he built a life science portfolio leading to five U.S. and European IPOs, including Devgen, Jerini, Addex, OMS, and Micrus, as well as trade sales (in some cases subsequent to IPO), including BiPar, Jerini and Micrus. Dr. Oster has also served on the Board of Directors at numerous companies, including as Chairman. Currently he is the CEO and Chairman of Oncoceutics, an oncology company he co-founded in 2009. He also serves as a guest lecturer at University of Pennsylvania’s Wharton School.